AllianceBernstein
RIGL icon

AllianceBernstein’s Rigel Pharmaceuticals RIGL Stock Holding History

AllianceBernstein’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-50,000
Closed -$1.15M – 3133
2018
Q4 		$1.15M Buy
+50,000
New +$1.41M ﹤0.01% 2130

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein's RIGL Position: Q1 2026 in Review

AllianceBernstein reduced its Rigel Pharmaceuticals (RIGL) stake by 8.8% in Q1 2026, selling an estimated $55.8K and leaving 17,233 shares worth $738K. The position accounts for ﹤0.01% of the portfolio, ranked #2458.

AllianceBernstein first reported a position in RIGL in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.31M in Q3 2018. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • AllianceBernstein held 17,233 shares of Rigel Pharmaceuticals worth $738K as of Q1 2026.
  • AllianceBernstein sold 1,660 Rigel Pharmaceuticals shares in Q1 2026, an estimated $55.8K.
  • Rigel Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2458 holding.
  • AllianceBernstein first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • AllianceBernstein's Rigel Pharmaceuticals position peaked at $4.31M in Q3 2018.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.